SCHEDULE: Armistice Capital Reports 4.99% Stake in Revelation Biosciences

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Revelation Biosciences, Inc. common stock.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed an amended Schedule 13G, indicating their beneficial ownership of Revelation Biosciences, Inc. common stock.
• The filing reports a total of 209,212 shares, representing 4.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The Master Fund, a client of Armistice Capital, has the right to receive dividends and proceeds from the sale of these securities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral filing, primarily an informational update on beneficial ownership rather than a significant strategic or financial event.

Positives

• Clear disclosure of beneficial ownership, enhancing transparency for investors.
• The reporting persons hold a significant, though below the 5% threshold for active disclosure, stake, suggesting potential interest in the company's performance.

Negatives

• The filing does not contain any new financial performance data or strategic initiatives, limiting its immediate impact on valuation.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, creating a layer of complexity in direct ownership attribution.

Risks

• Potential for future changes in beneficial ownership, which could impact share price dynamics.
• The filing does not provide insight into the investment strategy or intentions of Armistice Capital and Steven Boyd regarding Revelation Biosciences.

Future Outlook

This filing is an informational disclosure regarding beneficial ownership and does not contain forward-looking statements or guidance from the company.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in public companies. This filing indicates Armistice Capital's position in Revelation Biosciences, a biotechnology company, which is a sector often subject to substantial investor interest and potential volatility.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant beneficial ownership, potentially influencing market perception.
• Management of Revelation Biosciences: Awareness of a substantial shareholder whose investment decisions could impact the company's stock performance.

Next Steps

• Armistice Capital and Steven Boyd will continue to file amendments to Schedule 13G as required by SEC regulations for any material changes in beneficial ownership.
• Revelation Biosciences, Inc. will continue its operations and disclosures as a publicly traded entity.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Armistice Capital, Revelation Biosciences, Investment Management, Common Stock, SEC Filing